Adzenys ER oral suspension utilizes the same proprietary modified-release
drug delivery technology as Adzenys XR-ODT and is bioequivalent to Adderall XR.
gliclazide (Dosage: 60 mg, Lecture form: prolonged-release tablets, modified-release
Efficacy of modified-release
versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomized controlled trial.
Researchers gave 40 obese patients with diabetes three different types of aspirin in 325 mg doses: plain, modified-release
(liquid aspirin-filled capsules) and delayed-release enteric-coated (the kind designed to protect your stomach).
According to the company NT-0201, which is an Amphetamine XR oral suspension drug candidate, is an ADHD medication based on its proprietary modified-release
drug delivery technology platforms.
The acquired portfolio aligns with Mayne Pharma's focus in complex drug delivery formulations and technologies - and includes transdermal patches, gel capsules, semi-solids and modified-release
The company can now introduce commercial-scale manufacturing capability using solvent-based, fluid-bed processing technologies for modified-release
bead/pellet products--an offering Mayne Pharma provides at its Australia facility.
3) Long-term administration of 40 mg of modified-release
doxycycline, on the other hand, did not affect bacterial susceptibility over a 9-month period.
ortbo-Phthalates are used extensively as excipients (inactive ingre-dienrs) in modified-release
medications taken by mouth.
The authors performed a double-blind, randomized, placebo-controlled study of 2 g daily modified-release
NA added to statin therapy in 71 patients with low HDL-C (<40 mg/dl) and either type 2 diabetes with coronary heart disease or carotid/peripheral atherosclerosis.
formulation of prednisone reduced morning stiffness duration in patients with rheumatoid arthritis, according to data presented at the annual European Congress of Rheumatology.
A company spokeswoman said the FDA issued an "approvable letter," which indicated the agency has some unresolved concerns about the safety and efficacy of the modified-release